MedTrace Logo

Concentration of Trimethylamine Oxide (TMAO) in Blood Plasma as a Risk Factor for Vascular Cerebral Damage

NCT03903601 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-07-20

No results posted yet for this study

Summary

The primary aim of the current research project is to answer the question, whether plasma trimethylamine N-oxide (TMAO) level may be used as a marker of ischemic changes in the brain. TMAO is associated with endothelial dysfunction, inflammation and oxidative stress.

The hypothesis is that circulating TMAO level may predict leukoaraiosis (LA) and/or stroke.

Secondary, the investigators would like to examine whether plasma TMAO concentration is related to cognitive impairment and determine whether choline consumption is associated with an incidence of LA severity and dementia.

Conditions

  • Vascular Diseases
  • Leukoaraiosis
  • Ischemia, Cerebral

Interventions

DIAGNOSTIC_TEST

Magnetic Resonance Imaging (MRI)

Magnetic Resonance Imaging (MRI) to diagnose ischemic changes in the brain.

DIAGNOSTIC_TEST

Blood samples collection

Trimethylamine N-oxide (TMAO) concentration, oxidative stress markers and endothelial dysfunction markers will be determined in blood samples.

DIAGNOSTIC_TEST

Neuropsychological tests

Cognitive functions assessment

Sponsors & Collaborators

  • Gdansk University of Physical Education and Sport

    lead OTHER

Principal Investigators

  • Robert A Olek, PhD · Gdansk University of Physical Education and Sport

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-30
Primary Completion
2022-04-30
Completion
2022-05-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03903601 on ClinicalTrials.gov